Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Zenas BioPharma

Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis
From Zenas BioPharma
Via GlobeNewswire
Tickers ZBIO
Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis
From Zenas BioPharma
Via GlobeNewswire
Tickers ZBIO
Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million
From Zenas BioPharma
Via GlobeNewswire
Tickers RPRX ZBIO
Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences
From Zenas BioPharma
Via GlobeNewswire
Tickers ZBIO
Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
From Zenas BioPharma
Via GlobeNewswire
Tickers ZBIO
Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Zenas BioPharma
Via GlobeNewswire
Tickers ZBIO
Zenas BioPharma to Present at the Jefferies Global Healthcare Conference
From Zenas BioPharma
Via GlobeNewswire
Tickers ZBIO
Zenas BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Updates
From Zenas BioPharma
Via GlobeNewswire
Tickers ZBIO
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Zenas BioPharma
Via GlobeNewswire
Tickers ZBIO
Zenas BioPharma Appoints Haley Laken, Ph.D., as Chief Scientific Officer
From Zenas BioPharma
Via GlobeNewswire
Tickers ZBIO
Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer
From Zenas BioPharma
Via GlobeNewswire
Tickers ZBIO
Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases
From Zenas BioPharma
Via GlobeNewswire
Tickers ZBIO
Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference
From Zenas BioPharma
Via GlobeNewswire
Tickers ZBIO
Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
From Zenas BioPharma
Via GlobeNewswire
Tickers ZBIO
Zenas BioPharma Completes Targeted Enrollment of the Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)
From Zenas BioPharma
Via GlobeNewswire
Tickers ZBIO
Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences
From Zenas BioPharma
Via GlobeNewswire
Tickers ZBIO
Zenas BioPharma Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in Initial Public Offering
From Zenas BioPharma
Via GlobeNewswire
Tickers ZBIO
Zenas BioPharma Announces Pricing of Upsized Initial Public Offering
From Zenas BioPharma
Via GlobeNewswire
Zenas BioPharma Appoints Orlando Oliveira as Chief Commercial Officer
From Zenas BioPharma
Via GlobeNewswire
Zenas BioPharma Announces Upsized $200 Million Series C Financing to Advance Mid- and Late-Stage Immunology-Focused Clinical Development Programs
From Zenas BioPharma
Via GlobeNewswire
Zenas BioPharma Appoints Patricia Allen to its Board of Directors
From Zenas BioPharma
Via GlobeNewswire
Zenas BioPharma Strengthens Executive Leadership with Appointment of Jennifer Fox as Chief Business Officer and Chief Financial Officer and Tanya Fischer, M.D., PhD. as Head of R&D and Chief Medical Officer
From Zenas BioPharma
Via GlobeNewswire
Zenas BioPharma Announces Strategic License and Collaboration Agreement with Bristol Myers Squibb to Develop and Commercialize Novel Bi-Functional Antibody Obexelimab in Japan, South Korea, Taiwan, Singapore, Hong Kong and Australia
From Zenas BioPharma
Via GlobeNewswire
Zenas BioPharma Announces Publication of Phase 2 Study of Obexelimab, an Investigational Treatment for IgG4-Related Disease (IgG4-RD), in The Lancet Rheumatology
From Zenas BioPharma
Via GlobeNewswire
Zenas BioPharma Announces First Patient Dosed in Phase 3 Clinical Study of Obexelimab for the Treatment of Immunoglobulin G4-Related Disease (IgG4-RD)
From Zenas BioPharma
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.